Latest Conference Articles

Stay up to date on the latest oncology and nursing conferences.

Frontline Zanubrutinib/Rituximab, Short-Course R-DHAOx Elicits Preliminary Results in Mantle Cell Lymphoma

Frontline Zanubrutinib/Rituximab, Short-Course R-DHAOx Elicits Preliminary Results in Mantle Cell Lymphoma

January 17th 2023, 3:00pm

Among 17 patients with mantle cell lymphoma, the complete remission rate with first-line treatment with zanubrutinib plus rituximab followed by short-course rituximab plus dexamethasone, high-dose cytarabine, and oxaliplatin was 88.2%.

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

January 16th 2023, 7:00pm

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

Noncovalent BTK Inhibitors May Fill Unmet Needs in CLL and Other Top ASH Takeaways

Noncovalent BTK Inhibitors May Fill Unmet Needs in CLL and Other Top ASH Takeaways

January 12th 2023, 7:00pm

Laura J. Zitella, MS, RN, ACNP-BC, AOCN, highlights her top takeaways from the 64th American Society of Hematology Annual Meeting and Exposition.

Induction and Maintenance With Ibrutinib Proves Effective for Mantle Cell Lymphoma

Induction and Maintenance With Ibrutinib Proves Effective for Mantle Cell Lymphoma

January 12th 2023, 3:00pm

Adding induction to standard chemoimmunotherapy followed by autologous stem cell transplantation and maintenance ibrutinib was highly effective in patients with mantle cell lymphoma.

Zanubrutinib Outperforms Ibrutinib in Head-to-Head Trial for Relapsed/Refractory CLL/SLL

Zanubrutinib Outperforms Ibrutinib in Head-to-Head Trial for Relapsed/Refractory CLL/SLL

January 11th 2023, 7:00pm

Zanubrutinib demonstrated a superior reduction in the risk of progression or death for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma compared with ibrutinib.

Emerging Data Showcases Promising Advancements for Patients With HER2-Low Breast Cancer

Emerging Data Showcases Promising Advancements for Patients With HER2-Low Breast Cancer

January 9th 2023, 3:00pm

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP, reflects on data presented at the San Antonio Breast Cancer Symposium.

Sacituzumab Govitecan Continues to Prolong Survival in Patients With HR+/HER2– Breast Cancer

Sacituzumab Govitecan Continues to Prolong Survival in Patients With HR+/HER2– Breast Cancer

January 8th 2023, 3:00pm

Patients with hormone receptor–positive, HER2-negative metastatic breast cancer derived benefit with sacituzumab govitecan regardless of Trop-2 expression.

POSITIVE Study Findings Shift Conversations on Pregnancy in ER+ Breast Cancer

POSITIVE Study Findings Shift Conversations on Pregnancy in ER+ Breast Cancer

January 6th 2023, 7:00pm

Jamie Carroll, APRN, CNP, MSN, weighs in on how findings from the POSITIVE study may change dialogue surrounding pregnancy for women with estrogen receptor–positive breast cancer who wish to pause adjuvant therapy.

CBD Oil Shows Modest Improvements in Tamoxifen-Related Adverse Effects

CBD Oil Shows Modest Improvements in Tamoxifen-Related Adverse Effects

January 6th 2023, 3:00pm

Cannabidiol oil may be useful in helping patients with breast cancer manage tamoxifen-related adverse effects.

Antidiarrheal Prophylaxis Remains a Key Focus in TKI Treatment for Patients with HER2+ Breast Cancer

Antidiarrheal Prophylaxis Remains a Key Focus in TKI Treatment for Patients with HER2+ Breast Cancer

January 4th 2023, 7:00pm

Loperamide prophylaxis was linked to low rates of grade 3 diarrhea in patients receiving adjuvant pyrotinib, but better antidiarrheal prophylaxis options are still needed in this setting.